- Home
- HSCS vs RDHL Comparison
HSCS vs RDHL Comparison
Compare HSCS & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSCS | RDHL |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | Israel |
| Employees | 12 | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 5.4M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | HSCS | RDHL |
|---|---|---|
| Price | $2.63 | $0.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 4.4M | 93.0K |
| Earning Date | 03-16-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.63 | $0.69 |
| 52 Week High | $4.39 | $3.31 |
Technical Indicators
Market Signals| Indicator | HSCS | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 57.44 | 32.12 |
| Support Level | $2.61 | N/A |
| Resistance Level | $3.18 | $0.91 |
| Average True Range (ATR) | 0.41 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 48.77 | 3.92 |
Price Performance
Historical ComparisonAbout HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.